Acloproxalap

The FDA has accepted Aldeyra Therapeutics' resubmitted NDA for reproxalap, a potential first-in-class treatment for dry eye disease, with a PDUFA date of April 2, 2025.

Aldeyra Therapeutics plans to resubmit its NDA for reproxalap to treat dry eye disease after addressing FDA concerns.

Aldeyra Therapeutics' NDA for Reproxalap in dry eye disease has a PDUFA date of November 23, 2023, with commercial preparations underway, highlighting its potential in a $23 billion market.